Fed. Circ. Hands Sanofi Victory In Eloxatin Spat

By Elaine Meyer

Law360, New York (September 10, 2009, 6:24 PM ET) -- A federal appeals court has struck down a ruling in an infringement suit brought by Sanofi-Aventis US LLC against a slew of generics makers, saying the lower court erred when it said the generics manufacturers had not infringed on Sanofi’s patent for popular colon cancer drug Eloxatin.

The U.S. Court of Appeals for the Federal Circuit on Wednesday vacated and remanded a summary judgment ruling back to the U.S. District Court for the District of New Jersey.

Sanofi filed the suit in June 2007, accusing generic-drug...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles